The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Krasheninnikov A.A.

FGBU «Moskovskiĭ nauchno-issledovatelskiĭ onkologicheskiĭ institut im. P.A. Gertsena» Minzdrava Rossii

Alekseev B.Ia.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Niushko K.M.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Vorob'ev N.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im P.A. Gertsena"

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Treatment of patients with prostate cancer at high risk of its progression

Authors:

Krasheninnikov A.A., Alekseev B.Ia., Niushko K.M., Vorob'ev N.V., Kaprin A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2019;8(6): 460‑465

DOI: 10.17116/onkolog20198061460

Read: 6701 times

Download PDF (RU)
Contact the author
Table of contents

TREATMENT OF PATIENTS WITH PROSTATE CANCER AT HIGH RISK OF ITS PROGRESSION
TREATMENT OF PATIENTS WITH PROSTATE CANCER AT HIGH RISK OF ITS PROGRESSION

To cite this article:

Krasheninnikov AA, Alekseev BIa, Niushko KM, Vorob'ev NV, Kaprin AD. Treatment of patients with prostate cancer at high risk of its progression. P.A. Herzen Journal of Oncology. 2019;8(6):460‑465. (In Russ.)
https://doi.org/10.17116/onkolog20198061460

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pote­ntial of specialized diet therapy in redu­cing toxic mani­festations in patients with meta­static castration-resistant prostate cancer with bone meta­stases during radionuclide therapy with radium chlo­ride [223Ra]. P.A. Herzen Journal of Onco­logy. 2024;(6):33-41
Opti­mized inte­rdisciplinary approach in the treatment of maxi­llary sinus upper wall fractures in children. Russian Bulletin of Otorhinolaryngology. 2024;(5):29-34
Heavy eye syndrome: clinical mani­festations, diagnosis and treatment. Russian Annals of Ophthalmology. 2024;(5):112-117
Inte­rventional radiological and endo­scopic technologies in diagnosis and treatment of chro­nic pancreatitis. Piro­gov Russian Journal of Surgery. 2024;(11):84-93
Giant peri­cranial sinus with exte­nsive occi­pital calvarium defect. Burdenko's Journal of Neurosurgery. 2024;(6):77-87
Surgical treatment of asce­nding aortic dissection after previous thoracic endo­vascular aortic repair and proximal stent-graft indu­ced new entry. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):682-685
Patterns of CAF expression in tumors of the geni­tourinary system. Russian Journal of Archive of Pathology. 2024;(6):28-35
Impact of tumor size on actuarial survival of patients with primary breast sarcoma: a case-control study. Piro­gov Russian Journal of Surgery. 2024;(12):38-43
Long-term postoperative outcomes after surgical correction of congenital subaortic stenosis. Piro­gov Russian Journal of Surgery. 2024;(12):60-66
Difficulties in surgical treatment of fixed cardiofundal axial esophageal hiatal hernia. Piro­gov Russian Journal of Surgery. 2024;(12):105-108
Abstract:

Prostate cancer (PC) is one of the most pressing current challenges in oncology due to high incidence and mortality rates. At the time of diagnosis, about one third of patients are at high risk of disease progression. The issue of determining the treatment policy for patients with PC at high risk of its progression is presently debatable and extremely relevant. The main treatments for patients with high-risk nonmetastatic localized or locally advanced PC are surgery or radiation/hormone radiation therapy. The accumulation of surgical experience can substantially optimize the results of treatment in patients with PC and reduce the frequency of complications. However, large randomized prospective clinical trials are required to compare the efficiency of surgical treatment or radiation therapy and to establish their benefits. This review considers the most relevant information regarding the determination of treatment policy in patients with PC at high risk of its progression.

Keywords:

prostate cancer
high risk of progression
surgical treatment
radiation therapy
survival rates

Authors:

Krasheninnikov A.A.

FGBU «Moskovskiĭ nauchno-issledovatelskiĭ onkologicheskiĭ institut im. P.A. Gertsena» Minzdrava Rossii

Alekseev B.Ia.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Niushko K.M.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Vorob'ev N.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im P.A. Gertsena"

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Close metadata

References:

  1. Pernar C, Ebot E, Wilson K, Mucci L. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12).pii:a030361. https://doi.org/10.1101/cshperspect.a030361
  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebe- lo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):E359-E386. https://doi.org/10.1002/ijc.29210
  3. Kaprin AD, Starinskiy VV, Petrova GV, eds. Malignant tumors in Russia in 2016 (incidence and mortality). Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2018. (In Russ.)
  4. Ceylan C, Tonyali S, Keles I. Impact of positive surgical margin on biochemical recurrence following radical prostatectomy in locally advanced prostate cancer. Kaohsiung J Med Sci. 2016;32(10):514-517. https://doi.org/10.1016/j.kjms.2016.08.007
  5. Dar’yalova SL, Boiko AV, Alekseyev BYa, Grishina YuA. Radiotherapy for prostate cancer: procedure and results. Rossiyskiy onkologicheskiy zhurnal. 2006;(6):9-13. (In Russ.)
  6. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103-108. https://doi.org/10.1016/s0140-6736(02)09408-4
  7. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma — long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61(5):1285-1290. https://doi.org/10.1016/j.ijrobp.2004.08.047
  8. Badiozamani KR. Duration of androgen suppression in prostate cancer. N Engl J Med. 2009;361(12):1212-1213. https://doi.org/10.1056/nejmc091433
  9. Leal F, Figueiredo M, Sasse A. Optimal duration of androgen deprivation therapy following radiation therapy in intermediate — or high-risk non-metastatic prostate cancer: a systematic review and meta-analysis. Int Braz J Urol. 2015;41(3):425-434. https://doi.org/10.1590/s1677-5538.ibju.2014.0412
  10. Chang A, Autio K, Roach M, Scher H. High-risk prostate cancer — classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308-323. https://doi.org/10.1038/nrclinonc.2014.68
  11. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990-1996. https://doi.org/10.1200/jco.2005.05.2530
  12. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011;79(5):1310-1317. https://doi.org/10.1016/j.ijrobp.2010.01.006
  13. Mossanen M, Krasnow RE, Nguyen PL, Trinh QD, Preston M, Kibel AS. Approach to the patient with high-risk prostate cancer. Urol Clin North Am. 2017;44(4):635-645. https://doi.org/10.1016/j.ucl.2017.07.009
  14. Fang F, Wang Y, Wang C, Huang H, Chiang P. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus External Beam Radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol. 2008;38(7):474-479. https://doi.org/10.1093/jjco/hyn056
  15. Hoskin P, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol. 2007;84(2):114-120. https://doi.org/10.1016/j.radonc.2007.04.011
  16. Hoskin P, Rojas A, Bownes P, Lowe G, Ostler P, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(2):217-222. https://doi.org/10.1016/j.radonc.2012.01.007
  17. Soumarová R, Homola L, Perková H, štursa M. Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate: comparison of acute toxicity. Tumori J. 2007;93(1):37-44. https://doi.org/10.1177/030089160709300108
  18. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275-285. https://doi.org/10.1016/j.ijrobp.2016.11.026
  19. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23(6):1192-1199. https://doi.org/10.1200/jco.2005.06.154
  20. Martínez-Monge R, Moreno M, Ciérvide R, Cambeiro M, Pérez-Gracia JL, Gil-Bazo I, Gaztañaga M, Arbea L, Pascual I, Aristu J. External-beam radiation therapy and high–dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys. 2012;82(3):e469-e476. https://doi.org/10.1016/j.ijrobp.2011.08.002
  21. Bittner N, Merrick GS, Butler WM, Galbreath RW, Lief J, Adamovich E, Wallner KE. Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy. 2012;11(4):250-255. https://doi.org/10.1016/j.brachy.2012.02.002
  22. Meng M, Elkin E, Latini D, Duchane J, Carroll P. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol. 2005;173(5):1557-1561. https://doi.org/10.1097/01.ju.0000154610.81916.81
  23. Volchenko NN, Kaprin AD, Belyakov MM, Petrov AN. Comparative analysis of prostate cancer grades on biopsy and intraoperative materials. Onkologiya. Zhurnal imeni P.A. Gertsena. 2016;5(1):18-22. (In Russ.)
  24. Ward J, Slezak J, Blute M, Bergstralh E, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751-756. https://doi.org/10.1111/j.1464-410x.2005.05394.x
  25. Ghavamian R, Williams S, Hakimi A. High-risk prostate cancer: the role of radical prostatectomy for local therapy. Future Oncol. 2011;7(4):543-550. https://doi.org/10.2217/fon.11.22
  26. Cooperberg M, Carroll P. Trends in management for patients with localized prostate cancer, 1990—2013. JAMA. 2015;314(1):80. https://doi.org/10.1001/jama.2015.6036
  27. Mitchell C, Boorjian S, Umbreit E, Rangel L, Carlson R, Karnes R. 20-year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012;110(11):1709-1713. https://doi.org/10.1111/j.1464-410x.2012.11372.x
  28. Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, Kneitz B, Chun FK, Zaffuto E, Sun M, et al. Natural history of surgically treated high-risk prostate cancer. Urol Oncol. 2015;33(4):163.e7-e13. https://doi.org/10.1016/j.urolonc.2014.11.018
  29. Beauval JB, Roumiguié M, Filleron T, Benoit T, de la Taille A, Malavaud B, Salomon L, Soulié M, Ploussard G. Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer. BMC Urol. 2016; 16(1):26. https://doi.org/10.1186/s12894-016-0146-6
  30. Touijer K, Mazzola C, Sjoberg D, Scardino P, Eastham J. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol. 2014;65(1):20-25. https://doi.org/10.1016/j.eururo.2013.03.053
  31. Delporte G, Henon F, Ploussard G, Briganti A, Rizk J, Rozet F, Touijer K, Ouzzane A. Radical prostatectomy for locally advanced and high-risk prostate cancer: a systematic review of the literature. Prog Urol. 2018;28(16):875-889. https://doi.org/10.1016/j.purol.2018.08.007
  32. Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, Vickers A, Scardino PT. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28(9):1508-1513. https://doi.org/10.1200/jco.2009.22.2265
  33. Wallis CJD, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, Shah PS, Danjoux C, Nam RK. Surgery versus radiotherapy for clinically-localized prostate cancer: A systematic review and metaanalysis. Eur Urol. 2016;70(1):21-30. https://doi.org/10.1016/j.eururo.2015.11.010
  34. Robinson D, Garmo H, Lissbrant IF, Widmark A, Pettersson A, Gunnlaugsson A, Adolfsson J, Bratt O, Nilsson P, Stattin P. Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study. Eur Urol. 2018;73(4):502-511. https://doi.org/10.1016/j.eururo.2017.11.039
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.